MENU
Aim higher

ABC2ALL

Anti B-Cell 2-specific Antibody for the treatment of chronic Lymphocytic Leukaemia

ABC2ALL consortium will develop a novel therapeutic strategy to treat B-cell chronic lymphocytic leukemia (CLL). The consortium will design, produce and validate a therapeutic bispecific monoclonal antibody (mAb) that simultaneously targets two specific receptors expressed on malignant B-cells. This will provide improved efficacy, specificity, and safety when compared to the current treatment regimens. Upon completion of the project, the product will be ready for further clinical development.
Acronym: 
ABC2ALL
Project ID: 
10 506
Ranking: 
23
Cut-off: 
5
Start date: 
01-02-2017
Project Duration: 
36months
Project costs: 
2 641 060.00€
Technological Area: 
Pharmaceutical Products / Drugs
Market Area: 
Other therapeutic (including defibrillators)